Efficacy and Safety of Serelaxin when Added to Standard of Care in Patients with Acute Heart Failure: Results from a PROBE Study, RELAX-AHF-EU — Aldo Maggioni (2019) | RDL Network
When added to SoC, serelaxin reduced adjudicated WHF or all-cause death through Day 5 in AHF patients. The results from this open-label study should be considered in the context of the totality of the double-blind, randomised evidence on serelaxin in AHF.
Jonas Hallén, Aldo Maggioni, Esteban López de Sá, Fabio Maria Turazza, Klaus K. Witte, Erland Erdmann, Ulf Dahlström, Georg Ertl, Olav Wendelboe Nielsen, J. López Sendón, Thomas Holbro, Chien‐Wei Chen, Claudio Gimpelewicz, Martín Cowie
John R. Teerlink, Beth A. Davison, Gad Cotter, Aldo Maggioni, Naoki Sato, Ovidiu Chioncel, Georg Ertl, G. Michael Felker, Gerasimos Filippatos, Barry Greenberg, Peter S. Pang, Piotr Ponikowski, Christopher Edwards, Stefanie Senger, Sam L. Teichman, Olav Wendelboe Nielsen, Adriaan A. Voors, Marco Metra
Johannes Grand, Kristina Miger, Ahmad Sajadieh, Lars Køber, Christian Torp‐Pedersen, Georg Ertl, José López‐Sendón, Aldo Maggioni, Olav Wendelboe Nielsen
Francesco Orso, Andrea Di Lenarda, Fabrizio Oliva, Maria Luíza Anselmi, Nadia Aspromonte, Giuseppe Di Tano, Giovanni Leonardi, Donata Lucci, Aldo Maggioni, Andrea Mortara, Alessandro Navazio, Giovanni Pulignano, Michele Massimo Gulizia
Johannes Grand, Kristina Miger, Ahmad Sajadieh, Lars Køber, Christian Torp‐Pedersen, Georg Ertl, JL. Lopez Sendon, Aldo Maggioni, Olav Wendelboe Nielsen
Discussion(0)
No comments yet. Be the first to comment.